Politico May 28, 2024
CHECKUP
Most Americans who start using the new class of weight-loss drugs, such as Ozempic and Wegovy, aren’t sticking with them.
That’s according to a new study from the research arm of the Blue Cross Blue Shield Association of health insurers.
How so? Nearly 6 in 10 people who start the drugs quit before they reach a “clinically meaningful” health benefit. The drugs, which have been used to treat diabetes for years, reduce appetite by mimicking the GLP-1 hormone released in the gastrointestinal tract when we eat.
Twelve weeks of treatment is considered the optimum length of time to be considered clinically significant, the study found, as is losing 5 percent of body weight.
Yet, nearly a third of patients...
Today's Sponsors
Today's Sponsor